Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
Orexin B (Hypocretin-2)
Preclinical
Research chemical
Summary
Endogenous 28-amino-acid lateral-hypothalamic neuropeptide that preferentially activates OX2R to stabilize wakefulness, appetite, and arousal circuits.
Categories
Cognitive & Nootropic, Sleep
Mechanism
OX2R (and weaker OX1R) GPCR agonism on histaminergic TMN, noradrenergic LC, serotonergic raphe, and cholinergic arousal nuclei. Also modulates feeding and reward circuitry. Cardiac OX2R research suggests possible cardioprotective orexin-B signaling distinct from orexin-A.
Half-life
~5–10 minutes (rapid peptidase degradation)
Routes
Intravenous
Legal / access
Endogenous research neuropeptide; not an approved wake-promoting drug. Dual orexin receptor antagonists are the approved insomnia class (opposite direction).
Key risks
- Arousal/insomnia if central
- Cardiovascular effects theoretical
- No peripheral bioavailability
Common claims
- Alertness / anti-narcolepsy research interest
- Metabolic arousal
- Cardio-orexin research angle
Select peptide B